Novartis Acquires Spinifex Pharmaceuticals Inc.

Jun 29, 2015

Novartis has entered into an agreement to acquire Spinifex Pharmaceuticals Inc. Spinifex Pharmaceuticals is a U.S- and Australian-based development stage company focused on developing a peripheral approach to treat neuropathic pain such as EMA401, a novel angiotensin II Type 2 receptor (AT2R) antagonist.

It is estimated that up to 7 to 8% of the adult population suffer from chronic pain with neuropathic characteristics. Neuropathic pain is a chronic condition with high unmet medical need as approximately 40% of patients do not respond to current first-line treatment and a further 25% do not respond to second-line treatment options, according to a press release.

"Neuropathic pain is a chronic and debilitating condition with high unmet need. EMA401 could provide a novel, differentiated treatment approach to provide relief for patients and healthcare providers worldwide," said David Epstein, Head of Novartis Pharmaceuticals.

Positive results from Spinifex's Phase II clinical trial of EMA401 in post-herpetic neuralgia, a painful condition that develops in some people following herpes zoster (shingles), have been published in The Lancet[1], showing its efficacy. No central nervous system side effects or any serious adverse events have been observed in the study.

Read the full release

Return to the Pharma Mfg Newsletter

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments